ImmuPharma (LON:IMM) Shares Down 10% - Here's Why

Key Points

• ImmuPharma shares fell by 10% on Monday, trading as low as GBX 10.51 ($0.14) before closing at GBX 11.25 ($0.15).
• The company reported a negative P/E ratio of -1,264.38 and a net margin of 3,519.56%, reflecting significant financial challenges.
• ImmuPharma specializes in developing peptide-based therapeutics, with its lead program targeting Lupus and other autoimmune diseases.

ImmuPharma plc (LON:IMM - Get Free Report) shares were down 10% on Monday . The company traded as low as GBX 10.51 ($0.14) and last traded at GBX 11.25 ($0.15). Approximately 11,107,625 shares traded hands during trading, an increase of 30% from the average daily volume of 8,513,286 shares. The stock had previously closed at GBX 12.50 ($0.17).

ImmuPharma Stock Down 10.0%

The business's 50-day moving average is GBX 4.28 and its two-hundred day moving average is GBX 3.27. The company has a market capitalization of £56.23 million, a P/E ratio of -1,264.38 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.